1. First‐line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations
   Noriaki Ito et al, 2022, Thoracic Cancer CrossRef
2. The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC
   Fen Wang et al, 2022, Journal of Thoracic Oncology CrossRef
3. Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and A Literature Review
   Anna Rekowska et al, 2022, Current Oncology CrossRef
4. Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC
   Man Qiao et al, 2022, Emergency Medicine International CrossRef
5. Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
   Min-Kyung Yeo et al, 2022, Cancers CrossRef
6. Metal-Tyrosine Kinase Inhibitors: Targeted metal-drug conjugates
   Darren F. Beirne et al, 2022, Coordination Chemistry Reviews CrossRef
7. Emerging strategies to overcome resistance to third-generation EGFR inhibitors
   Kunyu Shi et al, 2022, J Hematol Oncol CrossRef
8. The role of mesenchymal-epithelial transition factor (c-MET) in cancer development and treatments
   Yuxuan Xie, 2022, HSET CrossRef
9. Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
   Chen Yan et al, 2022, Front. Pharmacol. CrossRef
10. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
    Wusheng Deng et al, 2022, BMJ Open CrossRef
11. An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy
    Khalid Saad Alharbi et al, 2022, Chemico-Biological Interactions CrossRef
12. Genetic alterations shaping tumor response to anti-EGFR therapies
    Javier Vaquero et al, 2022, Drug Resistance Updates CrossRef
13. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
    Yang Yang et al, 2022, Sig Transduct Target Ther CrossRef
14. Proteomic and Phosphoproteomic Analyses Reveal the Oncogenic Role of PTK7-NDRG1 Axis in Non-small-cell Lung Cancer Cell Resistance to AZD9291
    Zhen Wang et al, 2022, ACS Chem. Biol. CrossRef
15. PLEKHH2 binds β-arrestin1 through its FERM domain, activates FAK/PI3K/AKT phosphorylation, and promotes the malignant phenotype of non-small cell lung cancer
    Rui Wang et al, 2022, Cell Death Dis CrossRef
16. Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series
    Xinjing Ding et al, 2022, Oncol Lett CrossRef
17. Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
    Ruizhu Sun et al, 2022, Oncol Lett CrossRef
18. null
    Bengisu Dayanc et al, 2022 CrossRef
19. Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy
    Guoqing Zhang et al, 2022, Front. Oncol. CrossRef
20. Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
    Kun Pang et al, 2022, MedComm CrossRef
21. Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
    Hao Liu et al, 2022, Front. Oncol. CrossRef
22. Feiyanning formula modulates the molecular mechanism of osimertinib resistance in lung cancer by regulating the Wnt/β-catenin pathway
    Shuliu Sang et al, 2022, Front. Pharmacol. CrossRef
23. Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions
    Stephanie PL Saw et al, 2022, Curr. Treat. Options in Oncol. CrossRef
24. Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model
    Nadeem Moghal et al, 2022, Journal of Thoracic Oncology CrossRef
25. The Silkworm Carboxypeptidase Inhibitor Prevents Gastric Cancer Cells’ Proliferation through the EGF/EGFR Signaling Pathway
    Junhong Ye et al, 2023, IJMS CrossRef
26. First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review
    Marko Magdi Abdou Sidrak et al, 2023, Cancer Biotherapy and Radiopharmaceuticals CrossRef
27. MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
    Lu Bai et al, 2023, Front. Oncol. CrossRef
28. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma
    Ting Wang et al, 2023, BMC Pulm Med CrossRef
29. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
    Michael R. Sayer et al, 2023, Front. Oncol. CrossRef
30. Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes
    Weixin Zhao et al, 2023, BMC Med CrossRef
31. Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
    Jia Zhong et al, 2023, Front. Med. CrossRef
32. The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer
    Gabriela Bordeianu et al, 2023, Biomedicines CrossRef
33. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
    Martin Sattler et al, 2023, JCM CrossRef
34. Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer
    Jiajian Shi et al, 2022 CrossRef
35. Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study
    Adam Pluzanski et al, 2023, Cancers CrossRef
36. Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
    Nunzio Digiacomo et al, 2023, Current Oncology CrossRef
37. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
    Hédi Ben Yahia et al, 2023 CrossRef
38. Single-cell gene set enrichment analysis and transfer learning for functional annotation of scRNA-seq data
    Melania Franchini et al, 2023 CrossRef
39. Antitumor activity and mechanisms of dual EGFR/DNA-targeting strategy for the treatment of lung cancer with EGFRL858R/T790M mutation
    Lumei Dai et al, 2023, Bioorganic Chemistry CrossRef
40. A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy
    Bin Xu et al, 2023, Bioactive Materials CrossRef
41. The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway
    Yingqiu Yin et al, 2023, Heliyon CrossRef
42. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFRL858R/T790M inhibitors
    Jianfang Fu et al, 2023, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
43. Interpretable deep learning survival predictive tool for small cell lung cancer
    Dongrui Zhang et al, 2023, Front. Oncol. CrossRef
44. Determination of binding affinities between nuclear localization signal peptides of irradiated EGFR and KPNA using single‐molecule pull‐down assay and development of assay system for inhibitor screening
    Jiwon Oh et al, 2023, Bulletin Korean Chem Soc CrossRef
45. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
    Sushanta Halder et al, 2023, Expert Opinion on Therapeutic Targets CrossRef
46. Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy
    Lian Yu et al, 2023, Intl Journal of Cancer CrossRef
47. Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers
    D. Gwyn Bebb et al, 2023, Pulm Ther CrossRef
48. Arsenic Inhibits Proliferation and Induces Autophagy of Tumor Cells in Pleural Effusion of Patients with Non-Small Cell Lung Cancer Expressing EGFR with or without Mutations via PI3K/AKT/mTOR Pathway
    Jianhua Mao et al, 2023, Biomedicines CrossRef
49. Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report
    Aurélie Louvet et al, 2023, Front. Oncol. CrossRef
50. Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1
    Sewoong Lee et al, 2023, BMC Cancer CrossRef
51. Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report
    Lauren Schmalz et al, 2023, Lung Cancer CrossRef
52. Effects of cilengitide derivatives on TGF-β1-induced epithelial-to-mesenchymal transition and invasion in gefitinib-resistant non-small cell lung cancer cells
    Yujin Seo et al, 2023, Front. Pharmacol. CrossRef
53. miRNAs and exosomal miRNAs in lung cancer: New emerging players in tumor progression and therapy response
    Mehrdad Hashemi et al, 2023, Pathology - Research and Practice CrossRef
54. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases
    Kaixuan Bai et al, 2023, J Neurooncol CrossRef
55. In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes
    Salman Alamery et al, 2023, Medicina CrossRef
56. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy
    Jiao Zeng et al, 2023, Front. Immunol. CrossRef
57. Discovery of YS-363 as a highly potent, selective, and orally efficacious EGFR inhibitor
    Pengxing He et al, 2023, Biomedicine & Pharmacotherapy CrossRef
58. Radioresistance or/and radiosensitivity of head and neck squamous cell carcinoma: biological angle
    Chen-Xi Li et al, 2023, Oral Maxillofac Surg CrossRef
59. Synergistic anticancer effect by targeting CDK2 and EGFR–ERK signaling
    Jinhuan Wu et al, 2024 CrossRef
60. Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study
    J. Huang et al, 2023, Clinical Oncology CrossRef
61. Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer
    Yi-Lin Chen et al, 2023, Oncol Lett CrossRef
62. ZYZ384 suppresses the growth of EGFR‐mutant non‐small cell lung cancer by activating JNK/MAPK signaling pathway
    Xiao‐Wen Nie et al, 2023, Chem Biol Drug Des CrossRef
63. Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC
    Xiaoping Song et al, 2023, Arch. Pharm. Res. CrossRef
64. The emerging role of noncoding RNAs in the EGFR signaling pathway in lung cancer
    Syam Mohan et al, 2023, Pathology - Research and Practice CrossRef
65. A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications
    Qi Zhang et al, 2023, Molecules CrossRef
66. Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
    Ting-ting Lin et al, 2023, Acta Pharmacol Sin CrossRef
67. Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment
    Yongxia Chen et al, 2023, Front. Oncol. CrossRef
68. DARS2 promotes the occurrence of lung adenocarcinoma via the ERK/c‐Myc signaling pathway
    Tao Fang et al, 2023, Thoracic Cancer CrossRef
69. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: a scoping review.
    Alessia Belloni et al, 2023, Critical Reviews in Oncology/Hematology CrossRef
70. Rational synthesis and evaluation of 2,4-diamino-thieno[2,3-d]pyrimidines as antitumor agents
    Yumeng Gao et al, 2023, Journal of Saudi Chemical Society CrossRef
71. Mechanisms analysis for Formononetin counteracted‐Osimertinib resistance in non‐small cell lung cancer cells: From the insight into the gene transcriptional level
    Runyang Yin et al, 2024, Chem Biol Drug Des CrossRef
72. Adverse Effects of Gefitinib on Skin and Colon in a Lung Cancer Mouse Model
    Yalei Wang et al, 2024, PRA CrossRef
73. The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)
    Zhinan Cheng et al, 2023, Oncol Rep CrossRef
74. Comparison of EGFR Expression in Ameloblastoma and Odontogenic Keratocyst
    Soheila Mirzaee et al, 2023, J Res Dent Maxillofac Sci CrossRef
75. Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor
    Chuan Wang et al, 2024, Front. Immunol. CrossRef
76. The m6A methyltransferase RBM15 affects tumor cell stemness and progression of cervical cancer by regulating the stability of lncRNA HEIH
    Yi Quan et al, 2024, Experimental Cell Research CrossRef
77. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR‐TKIs
    Zhenbang Gu et al, 2024, Intl Journal of Cancer CrossRef
78. EGFR TKI resistance in lung cancer cells using RNA sequencing and analytical bioinformatics tools
    Mark C. Howell Jr. et al, 2022, Journal of Biomolecular Structure and Dynamics CrossRef
79. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation
    Tomoaki Sasaki et al, 2024, RadioGraphics CrossRef
80. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer
    Lei Zhao et al, 2024, IJMS CrossRef
81. A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
    Mai Suzuki et al, 2024, npj Precis. Onc. CrossRef
82. Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report
    Zhiming Wu et al, 2024, Front. Oncol. CrossRef
83. The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer
    Hai Xiang et al, 2024 CrossRef
84. Tumor Organoids: The Era of Personalized Medicine
    Natalia V. Rassomakhina et al, 2024, Biochemistry Moscow CrossRef
85. Single-cell transcriptomic sequencing data reveal aberrant DNA methylation in SMAD3 promoter region in tumor-associated fibroblasts affecting molecular mechanism of radiosensitivity in non-small cell lung cancer
    Fushi Han et al, 2024, J Transl Med CrossRef
86. Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy
    Zhulin Wang et al, 2024, Front. Oncol. CrossRef
87. Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy
    Ya-Tao Wang et al, 2024, Molecules CrossRef
88. Targeted therapeutic options in early and metastatic NSCLC-overview
    Gabriella Gálffy et al, 2024, Pathol. Oncol. Res. CrossRef
89. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study
    Rongbin Qi et al, 2023, Lung Cancer CrossRef
90. Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer
    Simona Pellecchia et al, 2024, Genome Med CrossRef
91. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
    Yajun Liu et al, 2024, Arch. Pharm. Res. CrossRef
92. BDTX-189, a novel tyrosine kinase inhibitor, inhibits cell activity via ERK and AKT pathways in the EGFR C797S triple mutant cells
    Rui Wang et al, 2024, Chemico-Biological Interactions CrossRef
93. Accuracy of machine learning in preoperative identification of genetic mutation status in lung cancer: A systematic review and meta-analysis
    Jinzhan Chen et al, 2024, Radiotherapy and Oncology CrossRef
94. Mechanistic Insights into Yifei Sanjie Pill's Regulation of EMT to Enhance Gefitinib Treatment effect in NSCLC by in silico analysis and experimental validation
    Ruisheng Zhou et al, 2024, Journal of Ethnopharmacology CrossRef
95. Acquired resistance to Osimertinib in advanced lung cancer: A case report
    Jiayi Xu et al, 2024, Asian Journal of Surgery CrossRef
96. Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities
    Bethany D. Latham et al, 2024, Drug Metab Dispos CrossRef
97. Synergistic Anticancer Effects of SMYD2 Inhibitor BAY-598 and Doxorubicin in Non-small Cell Lung Cancer
    Jiaqi Meng et al, 2024, Heliyon CrossRef
98. The efficacy of different immunotherapy strategies to NSCLC patients after resistance to EGFR-TKIs: A retrospective study
    Jiuyan Huang et al, 2024, Asian Journal of Surgery CrossRef
99. Emerging roles of long noncoding RNA H19 in human lung cancer
    Irfan Ahmad et al, 2024, Cell Biochemistry & Function CrossRef